Roivant Launches LISRAYA in Dermatomyositis, Eyes Uveitis and FcRn Readouts
核心洞察
Roivant Sciences (搜索) has begun the US launch of LISRAYA (搜索) (brepocitinib) in dermatomyositis (搜索), roughly three weeks in, with management describing the commercial approach as slow and steady.
Phase III data for brepocitinib in non-infectious uveitis (搜索) are expected in the second half of the year and could support a second registered indication.
Immunovant's anti-FcRn (搜索) antibody IMVT-1402 is due to report randomized Phase II rheumatoid arthritis (搜索) data and cutaneous lupus proof-of-concept results later this year.
Roivant Sciences (搜索) has entered the early commercial phase for LISRAYA (搜索) (brepocitinib) in dermatomyositis (搜索), roughly three weeks after approval, while advancing a pipeline that includes a second potential indication for the drug, an anti-FcRn (搜索) antibody through Immunovant and an inhaled therapy for pulmonary hypertension associated with interstitial lung disease (搜索) (PH-ILD).
Chief executive Matthew Gline said the company's launch approach in dermatomyositis (搜索) remains "slow and steady." He said it was too soon to draw conclusions on prescriptions, reimbursement or coverage, though he cited enthusiasm from key opinion leaders. "We're focused on the launch itself, and focused on net sales as the ultimate judgment," Gline said, adding that Roivant has not committed to specific launch metrics it will disclose on earnings calls.
Uveitis Readout Could Add a Second Indication
Roivant expects Phase III data for brepocitinib in non-infectious uveitis (搜索) during the second half of the year. Gline said the company has not yet seen the data. A successful result could support a second registered indication for LISRAYA (搜索).
Gline described non-infectious uveitis (搜索) as the third-leading cause of blindness in the United States and said therapeutic innovation in the condition has been limited. He said Roivant's Phase II results compared favorably with historical HUMIRA data, while noting that the comparison was across trials. He expects a base-case commercial position in patients whose disease is refractory to TNF therapies, with stronger data potentially supporting use earlier in treatment.
IMVT-1402 Readouts in Rheumatoid Arthritis and Cutaneous Lupus
Later this year, Roivant expects updates on IMVT-1402, an anti-FcRn (搜索) antibody developed through Immunovant, including randomized Phase II data in difficult-to-treat rheumatoid arthritis (搜索) and headline data from a cutaneous lupus erythematosus (搜索) (CLE) proof-of-concept study.
The rheumatoid arthritis (搜索) study enrolled patients who had failed at least two biologic classes. In the open-label portion, about 70% of patients achieved an ACR20 response, about 50% achieved ACR50 and about 35% achieved ACR70, according to Gline. He said the depth of those responses could make the randomized withdrawal portion of the trial harder to interpret, because patients would need to lose substantial responses to meet the primary endpoint.
Roivant's principal objective for the randomized data is to avoid findings that would prevent a Phase III program, Gline said. The larger question is the potential regulatory path, including the size and number of studies the FDA may require for a late-line rheumatoid arthritis (搜索) population with limited treatment options.
For CLE, Gline characterized the study as an "option bet" rather than a central part of the company's investment thesis. He said Roivant would need to see strong data to justify a Phase III investment, given a growing competitive field and the potential dosing advantages of other mechanisms. He also said a small CLE study would not independently validate or invalidate FcRn (搜索) inhibition across lupus-spectrum diseases.
Graves' Disease Positioned as a 2027 Catalyst
Graves' disease (搜索) represents a major 2027 catalyst for IMVT-1402. Gline said the biology is straightforward because pathogenic antibodies drive the disease, and he described the company's Phase II results as unequivocal. He also noted operational and endpoint risks, including limited modern trial precedent in Graves' disease and the complexity of anti-thyroid drug titration.
Roivant is studying patients who remain uncontrolled on anti-thyroid drugs or cannot discontinue them because of side effects. Gline said the company estimates there are approximately 350,000 uncontrolled Graves' disease (搜索) patients in the U.S. and approximately 20,000 patients annually who undergo thyroid removal surgery.
In Phase II, nearly 60% of patients were able to discontinue or meaningfully reduce anti-thyroid drugs while achieving thyroid hormone normalization, he said. He also said 17 of 21 patients remained controlled six months after discontinuing therapy. One Phase III study includes responder re-randomization intended to generate placebo-adjusted remission data.
Mosliciguat and Pipeline Sequencing
Following the positive Phase II result for mosliciguat, a once-daily inhaled soluble guanylate cyclase (搜索) stimulator, in PH-ILD, Roivant is reassessing the sequence and prioritization of additional indications. Gline said the company began its Phase III study at risk about six months earlier to avoid delays if the data were positive.
He said Roivant generally does not disclose a new indication until a study has begun, partly because FcRn (搜索) development is competitive and preserving a lead can be valuable. As current programs complete studies, including non-infectious uveitis (搜索) and Immunovant's Graves' disease (搜索) and myasthenia gravis (搜索) trials, Gline said the company expects capacity to initiate further studies across its portfolio.
On business development and potential asset sales, Gline said Roivant's default strategy is to build a larger, durable company around its current pipeline rather than sell core programs. He said the company remains economically driven and would consider sufficiently attractive offers.
Roivant Sciences (搜索) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with significant unmet medical needs, concentrating on immunology, dermatology, oncology and other specialty conditions through internally developed programs, external licensing and strategic acquisitions. The company organizes many of its drug-development activities through subsidiary companies known as "Vants," which advance individual therapeutic programs or groups of related assets while Roivant provides operational, scientific and strategic support.